Blackcurrant (BC) extract

Phase 1Small molecule

UUniversity of Connecticut

Blackcurrant (BC) extract is one of 34 small molecule programs targeting Osteoporosis. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

OsteoporosisActive, not recruiting

OsteoporosisPhase 1

Active, not recruiting

Competition

Competitive Landscape

172 competitors in Osteoporosis

#DrugCompanyPhaseTrials

Boniva

CConrado Roberto Hoffmann Filho

Phase 3

26 2

Actonel

VVitae Pharmaceuticals Inc., an Allergan affiliate

Phase 3

16 3

Depo-Provera

Tymlos

2 5

Oxycodone IR

Johnson & Johnson

Phase 3

1 6

Salmon Calcitonin

Novartis

Phase 3

1 7

Ibandronic Acid

Roche

Phase 3

1 8

Effcamgcit

UUniversity of Texas Southwestern Medical Center

Phase 3

1 9

Prolia

Amgen

Preclinical

22 10

Prolia

Qilu Pharmaceutical Co., Ltd.

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2029

Phase 1Not yet recruiting

Osteoporosis

NCT07365514

Clinical

Trials by Indication[1]

Osteoporosis2 trials

Blackcurrants Modify Gut Microbiota and Reduce Osteoporosis Risk in Postmenopausal Females

Not yet recruiting·UUniversity of Connecticut·Phase 1·NCT07365514·159 enrolled

Blackcurrants Modify Gut Microbiota and Reduce Osteoporosis and CVD Risk

Completed·UUniversity of Connecticut·Phase 1·NCT04431960·51 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for Blackcurrant (BC) extract. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Blackcurrant (BC) extract compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Blackcurrant (BC) extract. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — University of Connecticut company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 1[1]
Company: UUniversity of Connecticut

Blackcurrant (BC) extract

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q3 2029

Trials by Indication[1]

Osteoporosis2 trials

References

Drug Info

Quick Facts

Related News